Ascendis Pharma (ASND) Tops Q4 EPS by 37c

Ascendis Pharma (NASDAQ: ASND) reported Q4 EPS of (EUR1.54), EUR0.37 better than the analyst estimate of (EUR1.91). Revenue for the quarter came in at EUR137.7 million versus the consensus estimate of EUR85.87 million.

For earnings history and earnings-related data on Ascendis Pharma (ASND) click here.

You May Also Be Interested In

• Citi cuts Micron stock target, sees memory chip prices peaking in 2Q27
• Minerva Neurosciences (NERV) Tops Q2 EPS by 5c
• bioAffinity (BIAF) Tops Q2 EPS by 146c